Board summary
Key figures
43,689
Registered population
53.5% aged 18–64
30.1%
Aged 65+
ICB 24.3% · England 17.9%
2.3%
Ethnic minority (non-White)
0.7% Asian · England 9.6%
4.0%
In IMD quintile 1
ICB 10.9% · England 21.0%
~1,522
Core20 residents (est.)
Resident basis; registered basis ~1,697 · see page 3
8,533
Hypertension register
+4.67% in 3 yrs · England +5.60%
322
SMI register
18.7% of Herefordshire, County of (LAD)'s
1,017
COPD register
Reviews +12.57% in 3 yrs
Forecast to 2030
9,670
Hypertension patients, 2030
+1,137 on today
89.8%
QRISK ≥20% on statins, 2030
+11.41pp over 3 yrs
6.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma patients without a recorded annual review.
Annual asthma reviews cover 64.2% of the 3,029 register (England 65.7%, ICB 66.4%), leaving a scale gap of 1,085 unreviewed patients.
High-risk QRISK patients on lipid-lowering therapy.
Lipid-lowering therapy for patients with QRISK ≥ 20% stands at 57.9%, trailing Herefordshire (59.6%), the ICB (61.4%) and England (63.6%).
Hypertension and diabetes control exceed national benchmarks.
Blood pressure treatment to target reaches 73.4% (England 70.3%) and non-frail diabetes HbA1c control reaches 63.5% (England 57.4%).
Population, age and ethnicity
Patients aged 65+ make up 30.1% of the list, well above England's 17.9%
Patients aged 65+ make up 30.1% (13,150) of the 43,689 registered list, above Herefordshire LAD (28.3%), the ICB (24.3%) and England (17.9%). Working-age adults (18-64) account for 53.5% and children (0-17) 16.4%. Census resident estimates indicate 97.7% White ethnicity, against 96.9% in the LAD, 94.6% in the ICB and 81.1% in England, with an ethnic minority share of 2.3%. This older age structure is consistent with high frailty and chronic disease workload, though resident ethnicity figures do not capture practice-level registered patient diversity.
Age profile
65+: ICB 24.3%, England 17.9%
Ethnicity
Older people · falls rows are Herefordshire, County of (LAD) local-authority (LA) data, not PCN
| Measure | Local | West Midlands | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Herefordshire LA) | 1,472 | 1,847 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.6% | — | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 63.5% | — | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Herefordshire LA) | 772 | 922 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Herefordshire LA) | 10.4 | 17.5 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation affects 4.0% of patients and concentrates entirely in two practices
The PCN Core20 share is 4.0%, below Herefordshire LAD (7.8%), the ICB (10.9%) and England (21.0%), with an average IMD decile of 5.6. Practice-level estimates (totalling 1,697 patients) and resident counts (1,522 across 1 decile-2 LSOA) reflect different bases and do not reconcile directly. Core20 workload concentrates entirely in Alton Street Surgery (9.8%, estimated 1,141 patients) and Pendeen Surgery (6.3%, 556 patients). Focusing preventative outreach on these two practices directs resources to the PCN's entire recorded Core20 cohort.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
322
SMI register
0.73% recorded prevalence
250
Learning disability register
0.57% recorded prevalence
26
Care homes, 612 beds
In the PCN catchment
8.7%
Provide unpaid care
Herefordshire, County of (LAD), Census 2021
The PCN records 250 learning disability patients (0.6%, matching England's 0.6%) and 322 severe mental illness patients (0.7%, below England's 1.0%), alongside 26 catchment care homes with 612 beds. Across Herefordshire local authority, Census data recorded 8.7% unpaid carers, and the rough sleeping snapshot was 16 people in autumn 2025. Crude recorded prevalence does not establish unmet need or under-detection.
Severe mental illness: physical health checks
Across 322 SMI patients, annual checks trail England on blood pressure (80.2% vs 83.4%), BMI (78.4% vs 82.1%), and alcohol recording (75.1% vs 81.8%). Prioritising combined physical health clinics could close these component gaps.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,533
Hypertension register
+4.67%
Register growth, 3 yrs
Herefordshire, County of (LAD) +10.36% · England +5.60%
+6.31pp
BP control, under 80
≤140/90 · +3.74pp aged 80+
+1,137
More patients by 2030
Forecast 9,670 (21.28%)
Hypertension case-finding and control
Hypertension prevalence is 19.4% (8,533 patients), above England (15.2%), LAD (19.2%) and ICB (18.7%), with three-year growth of +4.7% (England +5.6%). Blood pressure treated to target reaches 73.4%, exceeding England (70.3%), LAD (68.6%) and ICB (70.4%), leading national rates in patients aged under 80 (70.2% vs 67.8%) and 80+ (82.9% vs 81.2%). However, recent blood pressure checks cover 89.6%, below England (90.0%), LAD (90.3%) and ICB (90.6%), with three-year recording growth (+1.9%) trailing England (+3.6%). While blood pressure control is well maintained, slower monitoring growth points to an opportunity to tighten annual blood pressure recall across this large caseload.
Lipids and statins
For patients with QRISK ≥ 20%, lipid-lowering therapy coverage is 57.9%, trailing England (63.6%), LAD (59.6%) and ICB (61.4%), despite +24.6% three-year growth (England +6.2%). In CKD, coverage reaches 69.0% (England 70.3%). Fewer high-risk patients receive lipid therapy than national benchmarks, making proactive QRISK recall a priority.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 103,386 | £2.30 | £2.17 | £1.86 | £237,788 |
| Cardiovascular (all), 2025 | 127,766 | £4.38 | £4.41 | £3.33 | £559,615 |
In 2026, the PCN prescribed 103,386 lipid-regulating items at £2.30 per item (annual spend £237,788), compared with £1.86 in England, £2.44 in the LAD and £2.17 in the ICB. Across 103,386 items, this is £45,490 more than at England's unit cost. Higher unit costs than England suggest reviewing drug selection while maintaining clinical coverage.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+3.95%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+3.67%
Asthma prevalence, PCN 3-yr % change
COPD annual reviews reached 77.1% across 1,017 registered patients (prevalence 2.3%), up +12.6% over 2023 to 2025 (England +2.8%). Asthma reviews covered 64.2% of 3,029 patients (England 65.7%, ICB 66.4%), leaving an estimated 1,085 patients without a recorded review, while paediatric asthma second-hand smoke recording reached 74.3% (226 patients; England 78.8%). Focused call-recall may help address unreviewed asthma patients.
Cancer register and children's immunisation
Cancer register prevalence is 5.4% (2,385 patients), exceeding England (3.8%). In Q1 2025/26, 12-month 6-in-1 coverage reached the 95.0% target at 95.0% (England 91.0%). However, age-5 coverage was below the 95.0% target: MMR dose 2 was 88.0% (7 pp below target) and 4-in-1 booster was 86.7% (8.3 pp below target). Proactive recall before school entry could help lift preschool booster uptake.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
56.2%
Herefordshire and Worcestershire ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~770
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Herefordshire and Worcestershire ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 52.4% | 53.2% | 23% | 706 |
| Bowel | 51.4% | 47.0% | 15% | 657 |
| Breast | 88.9% | 85.4% | 28% | 611 |
| Lung | 32.1% | 33.8% | 13% | 473 |
| Skin cancer | 86.3% | 87.8% | 13% | 314 |
Across NHS Herefordshire and Worcestershire ICB in 2022, 56.2% of staged cancers (2,285 of 4,068) were diagnosed at stage 1 or 2, 18.8 pp below the 75.0% national ambition. Reaching 75.0% requires about 770 extra early diagnoses annually across the ICB, while early-stage share fell 2.7 pp between 2013 and 2022. Known-stage completeness was 68.0% (4,068 of 5,984 cancers). System figures reflect diagnostic staging rather than PCN performance. Meanwhile, PCN cervical screening coverage is 71.3% (England 66.8%), though Pendeen Surgery trails at 65.1% and Alton Street Surgery at 68.3%. Screening recall should prioritize practices trailing benchmarks.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
For July 2026 (provisional), main acute provider Wye Valley NHS Trust achieved 85.1% on the 62-day referral-to-treatment standard, meeting the 85.0% standard and outperforming England (71.2%), Gloucestershire Hospitals NHS Foundation Trust (74.6%), and Worcestershire Acute Hospitals NHS Trust (53.0%), while NHS Herefordshire and Worcestershire Integrated Care Board stood at 61.7%. Wye Valley reached 86.5% on the 28-day faster diagnosis standard (ICB 83.0%; England 79.3%) and 96.2% on 31-day combined treatment. Diagnostic six-week waits at Wye Valley were 0.2% for computed tomography and 18.2% for magnetic resonance imaging.
| Pathways within standard (%) | Wye Valley | Gloucestershire | Worcestershire Acute | Herefordshire and Worcestershire ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 86.52 | 74.43 | 82.50 | 83.05 | 79.32 |
| 31-day treatment (96%) | 96.25 | 94.66 | 86.98 | 89.95 | 92.50 |
| 62-day referral to treatment (85%) | 85.14 | 74.59 | 52.99 | 61.71 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Wye Valley | Gloucestershire | Worcestershire Acute | England |
|---|---|---|---|---|
| MRI | 18.23 | 15.96 | 22.51 | 21.40 |
| CT | 0.16 | 7.44 | 11.09 | 9.92 |
| Echocardiography | 30.24 | 56.17 | 10.25 | 28.48 |
| Colonoscopy | 40.00 | 40.00 | 9.91 | 30.83 |
| Gastroscopy | 26.09 | 31.55 | 9.53 | 29.02 |
| All 15 DM01 tests | 19.35 | 18.34 | 30.61 | 23.14 |
| Community services activity | Herefordshire, County of residents | Herefordshire and Worcestershire ICB |
|---|---|---|
| Care contacts | 43,135 | 124,085 |
| Referrals | 5,970 | 23,130 |
| Patients with a contact | 9,550 | 30,665 |
Community services (residents of Herefordshire, County of), Jun 2026 (provisional). In the Community Services Dataset for June 2026 (provisional), 67.4% of community service contacts for Herefordshire local authority residents were with adults aged 65 and over (29,080 of 43,135 total contacts). This activity captures authority residents rather than specific PCN cohorts.
Practice variation and patient experience
GP contact ease spans 21.8 pp and vaccination achievement varies by 58.2 pp
All six practices achieved 100.0% in QOF clinical (England 97.1%). Overall points ranged from 91.3% at Much Birch Surgery to 98.0% at Golden Valley Practice. Vaccination achievement spanned 58.2 pp; Much Birch Surgery reached 23.7% and Alton Street Surgery reached 48.0%, trailing England (55.2%). Personalized care adjustment rates spanned 5.2% at Golden Valley Practice to 11.2% at Pendeen Surgery.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Kingstone | 124 | 0.0 | 93.9% | 78.6% | 97.6% |
| Golden Valley | 99 | 0.0 | 76.6% | 75.8% | 88.7% |
| Alton Street | 123 | 9.8 | 78.5% | 71.7% | 88.5% |
| Much Birch Surgery | 102 | 0.0 | 88.6% | 79.1% | 88.1% |
| Pendeen Surgery | 115 | 6.3 | 72.1% | 74.1% | 83.4% |
| Fownhope | 117 | 0.0 | 78.9% | 71.6% | 78.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
SMI check trends lag England while heart failure reviews fell over three years
Three-year progress trails England most visibly across severe mental illness physical health checks: blood pressure recording rose +0.7 pp (England +4.4 pp) to 80.2%, BMI recording rose +1.5 pp (England +5.1 pp) to 78.4%, and alcohol recording rose +2.4 pp (England +5.4 pp) to 75.1%. Heart failure reviews fell 4.6% relative over three years (England +8.7%), despite current review completion reaching 81.0% (England 78.5%). Conversely, high-risk statin initiation showed relative growth of +24.6% (England +6.2%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
BP check (SMI)
BMI record (SMI)
Alcohol record (psychosis)
Hypertension BP reading
QRISK statin treatment
COPD reviews
Breast screening (53-70)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Herefordshire, County of (LAD) | Asset | PCN | Herefordshire, County of (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 26 (612 beds) | n/a | Schools (catchment) | 56 | n/a |
| Children's centres | 1 | 7 | Places of worship | 162 | 341 |
| Libraries | 1 | 9 | Day centres (VCS) | n/a | 1 |
| Carers support groups (VCS) | n/a | 1 | Primary schools (LA maintained) | 18 | 43 |
| Primary academies | 9 | 28 | Special schools | 1 | 4 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
64.2% of the 3,029 asthma register had a review in the last 12 months (England 65.7%, LAD 64.8%, ICB 66.4%), leaving a scale gap of 1,085 patients. For discussion: the PCN could run standardised asthma recall and flexible clinics, starting in the two Core20 practices. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Bundled SMI physical health checks
Across 322 SMI patients, annual checks trail England on BP (80.2% vs 83.4%), BMI (78.4% vs 82.1%) and alcohol recording (75.1% vs 81.8%); patient gap is not sized. For discussion: practices could offer bundled single-appointment SMI physical health checks and align template coding with mental health partners. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
High-risk QRISK lipid therapy recall
Lipid-lowering therapy for QRISK ≥ 20% is 57.9% (incl. PCAs), trailing England (63.6%), LAD (59.6%) and ICB (61.4%); patient gap is not sized. For discussion: the PCN could run pharmacist-led recall of untreated QRISK ≥ 20% patients alongside a formulary review (£2.30 per item vs England £1.86). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Anticipatory frailty reviews (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 practice outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall audit (p5) | Hypertension patients with a recent blood pressure reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool booster recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening uptake improvement (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | Practice |
| Primary care telephony access review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Core20 cohort (IMD quintile 1) | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · Bundled SMI physical health checks (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Option 3 · High-risk QRISK lipid therapy recall (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · Cost per item for Lipid-regulating drugs 2026 | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
